Matthias Calamia

4PUBLICATIONS
7CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 03, 2024
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Jul 17, 2024
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Dec 06, 2021
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities.

Briana M Choi, Rachel B Abraham, Hala Halawah

|Dec 06, 2021
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL.

Matthias Calamia, Ali McBride, Ivo Abraham

Pageof 1

Frequent Collaborators

2 joint publications

Ivo Abraham

2 joint publications

Nimer Alkhatib

2 joint publications

Marc Pondel

2 joint publications

Karen MacDonald